The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
No sooner does one gammadelta-focused biotech die than another takes its place.
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
The two companies have been involved in recent licensing deals.
